{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:20:20Z","timestamp":1774984820547,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Insurance claims data have been used to inform an understanding of Lyme disease epidemiology and cost of care, however few such studies have incorporated post-treatment symptoms following diagnosis. Using longitudinal data from a private, employer-based health plan in an endemic US state, we compared outpatient care utilization pre- and post-Lyme disease diagnosis. We hypothesized that utilization would be higher in the post-diagnosis period, and that temporal trends would differ by age and gender.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Members with Lyme disease were required to have both a corresponding ICD-9 code and a fill of an antibiotic indicated for treatment of the infection within 30 days of diagnosis. A 2-year \u2018pre- diagnosis\u2019 period and a 2-year \u2018post-diagnosis period\u2019 were centered around the diagnosis month. Lyme disease-relevant outpatient care visits were defined as specific primary care, specialty care, or urgent care visits. Descriptive statistics examined visits during these pre- and post-diagnosis periods, and the association between these periods and the number of visits was explored using generalized linear mixed effects models adjusting for age, season of the year, and gender.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The rate of outpatient visits increased 26% from the pre to the post-Lyme disease diagnosis periods among our 317-member sample (rate ratio\u2009=\u20091.26 [1.18, 1.36], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Descriptively, care utilization increases appeared to persist across months in the post-diagnosis period. Women\u2019s care utilization increased by 36% (1.36 [1.24, 1.50], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), a significantly higher increase than the 14% increase found among men (1.14 [1.02, 1.27], <jats:italic>p<\/jats:italic>\u2009=\u20090.017). This gender difference was mainly driven by adult members. We found a borderline significant 17% increase in visits for children\u2009&lt;\u200918 years, (1.17 [0.99, 1.38], <jats:italic>p<\/jats:italic>\u2009=\u20090.068), and a 31% increase for adults\u2009\u2265\u200918 years (1.31 [1.21, 1.42], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although modest at the population level, the statistically significant increases in post-Lyme diagnosis outpatient care we observed were persistent and unevenly distributed across demographic and place of service categories. As Lyme disease cases continue to grow, so will the cumulative prevalence of persistent symptoms after treatment. Therefore, it will be important to confirm these findings and understand their significance for care utilization and cost, particularly against the backdrop of other post-acute infectious syndromes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-09909-3","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:03:04Z","timestamp":1693314184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outpatient visits before and after Lyme disease diagnosis in a Maryland employer-based health plan"],"prefix":"10.1186","volume":"23","author":[{"given":"Alison W.","family":"Rebman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill A.","family":"Marsteller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M. E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Uriyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N.","family":"Aucott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"9909_CR1","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","volume":"2","author":"AC Steere","year":"2016","unstructured":"Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. https:\/\/doi.org\/10.1038\/nrdp.2016.90.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9909_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3201\/eid2702.202731","volume":"27","author":"KJ Kugeler","year":"2021","unstructured":"Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of lyme disease diagnoses, United States, 2010\u20132018. Emerg Infect Dis. 2021;27(2):616.","journal-title":"Emerg Infect Dis"},{"key":"9909_CR3","doi-asserted-by":"crossref","unstructured":"Stone BL, Tourand Y, Brissette CA. Brave new worlds: the expanding universe of Lyme disease. Vector-Borne and Zoonotic Diseases. Mary Ann Liebert Inc. 2017;17(9):619\u201329.","DOI":"10.1089\/vbz.2017.2127"},{"key":"9909_CR4","unstructured":"Centers for Disease Control and Prevention. Lyme Disease Data and Surveillance. Available from: https:\/\/www.cdc.gov\/lyme\/datasurveillance\/index.html. [Cited 2022 Sep 26]."},{"issue":"4","key":"9909_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00124784-199623000-00017","volume":"2","author":"JI Meek","year":"1996","unstructured":"Meek JI, Roberts CL, Smith EV Jr, Cartter ML. Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract. 1996;2(4):61\u20135.","journal-title":"J Public Health Manag Pract"},{"issue":"5","key":"9909_CR6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/infdis\/173.5.1260","volume":"173","author":"BS Coyle","year":"1996","unstructured":"Coyle BS, Strickland GT, Liang YY, Pe\u00f1a C, McCarter R, Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis. 1996;173(5):1260\u20132. https:\/\/doi.org\/10.1093\/infdis\/173.5.1260.","journal-title":"J Infect Dis"},{"issue":"2","key":"9909_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3201\/eid2702.202728","volume":"27","author":"AM Schwartz","year":"2021","unstructured":"Schwartz AM, Kugeler KJ, Nelson CA, Marx GE, Hinckley AF. Use of commercial claims data for evaluating trends in Lyme disease diagnoses, United States, 2010\u20132018. Emerg Infect Dis. 2021;27(2):499\u2013507. https:\/\/doi.org\/10.3201\/eid2702.202728.","journal-title":"Emerg Infect Dis"},{"key":"9909_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fmed.2020.00057","volume":"7","author":"AW Rebman","year":"2020","unstructured":"Rebman AW, Aucott JN. Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Front Med (Lausanne). 2020;7:57.","journal-title":"Front Med (Lausanne)"},{"key":"9909_CR9","doi-asserted-by":"publisher","unstructured":"Rebman A, Bechtold K, Yang T, Mihm E, Soloski M, Novak C et al. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med (Lausanne). 2018\/01\/10. 2017;4:224.https:\/\/doi.org\/10.3389\/fmed.2017.00224.","DOI":"10.3389\/fmed.2017.00224"},{"issue":"2","key":"9909_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM200107123450202","volume":"345","author":"MS Klempner","year":"2001","unstructured":"Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton DeLona, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85\u201392. https:\/\/doi.org\/10.1056\/NEJM200107123450202.","journal-title":"N Engl J Med"},{"issue":"6","key":"9909_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.psym.2013.04.003","volume":"54","author":"AM Chandra","year":"2013","unstructured":"Chandra AM, Keilp JG, Fallon BA. Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy. Psychosomatics. 2013;54(6):552\u20139. https:\/\/doi.org\/10.1016\/j.psym.2013.04.003.","journal-title":"Psychosomatics"},{"issue":"5","key":"9909_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","volume":"28","author":"J Choutka","year":"2022","unstructured":"Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911\u201323 (Available from: https:\/\/www.nature.com\/articles\/s41591-022-01810-6 [Cited 2022 Jun 13]).","journal-title":"Nat Med"},{"issue":"1","key":"9909_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12889-019-6681-9","volume":"19","author":"A DeLong","year":"2019","unstructured":"DeLong A, Hsu M, Kotsoris H. Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health. 2019;19(1):352. https:\/\/doi.org\/10.1186\/s12889-019-6681-9.","journal-title":"BMC Public Health"},{"issue":"1","key":"9909_CR14","doi-asserted-by":"publisher","first-page":"e0210280","DOI":"10.1371\/journal.pone.0210280","volume":"14","author":"S Mac","year":"2019","unstructured":"Mac S, da Silva SR, Sander B. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: a scoping review. PLoS One. 2019;14(1):e0210280 (Favato G, editor).","journal-title":"PLoS One"},{"issue":"2","key":"9909_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116767","volume":"10","author":"ER Adrion","year":"2015","unstructured":"Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS ONE. 2015;10(2): e0116767. https:\/\/doi.org\/10.1371\/journal.pone.0116767.","journal-title":"PLoS ONE"},{"issue":"4","key":"9909_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.diagmicrobio.2016.04.012","volume":"85","author":"E Weitzner","year":"2016","unstructured":"Weitzner E, Visintainer P, Wormser GP. Comparison of males versus females with culture-confirmed early Lyme disease at presentation and at 11\u201320 years after diagnosis. Diagn Microbiol Infect Dis. 2016;85(4):493\u20135. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.04.012.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"9909_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1089\/jwh.2008.1193","volume":"18","author":"GP Wormser","year":"2009","unstructured":"Wormser GP, Shapiro ED. Implications of gender in chronic Lyme disease. J Womens Health (Larchmt). 2009;18(6):831\u20134. https:\/\/doi.org\/10.1089\/jwh.2008.1193.","journal-title":"J Womens Health (Larchmt)"},{"issue":"17","key":"9909_CR18","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJM199610243351703","volume":"335","author":"MA Gerber","year":"1996","unstructured":"Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. N Engl J Med. 1996;335(17):1270\u20134. https:\/\/doi.org\/10.1056\/NEJM199610243351703.","journal-title":"N Engl J Med"},{"issue":"11","key":"9909_CR19","first-page":"2249","volume":"25","author":"TJ Wang","year":"1998","unstructured":"Wang TJ, Sangha O, Phillips CB, Wright EA, Lew RA, Fossel AH, et al. Outcomes of children treated for Lyme disease. J Rheumatol. 1998;25(11):2249\u201353.","journal-title":"J Rheumatol"},{"issue":"4 I","key":"9909_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1542\/peds.102.4.905","volume":"102","author":"MA Gerber","year":"1998","unstructured":"Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics. 1998;102(4 I):905\u20138.","journal-title":"Pediatrics"},{"issue":"10","key":"9909_CR21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1093\/aje\/kwy133","volume":"187","author":"AW Rebman","year":"2018","unstructured":"Rebman AW, Wang L, Yang T, Marsteller JA, Murphy SME, Uriyo M, Rebman AW, Wang L, Yang T, Marsteller JA, Murphy SME, Uriyo M, Mihm EA, Weinstein ER, Fagan P, Aucott JN. Incidence of Lyme Disease diagnosis in a maryland medicaid population, 2004\u20132011. Am J Epidemiol. 2018;187(10):2202\u20139. https:\/\/doi.org\/10.1093\/aje\/kwy133.","journal-title":"Am J Epidemiol"},{"key":"9909_CR22","unstructured":"Medicode (Firm), editor. Medicode. ICD-9-CM: International classification of diseases, 9th revision, clinical modification. 5th ed. Salt Lake City;\u00a01997. https:\/\/www.worldcat.org\/title\/icd-9-cm-international-classification-of-diseases-9th-revision-clinicalmodification\/oclc\/33167902."},{"key":"9909_CR23","unstructured":"Centers for Disease Control and Prevention. Lyme disease graphs: confirmed Lyme disease cases by month of disease onset-United States, 2001\u20132010. Available from: http:\/\/www.cdc.gov\/lyme\/stats\/chartstables\/casesbymonth.html."},{"key":"9909_CR24","unstructured":"United States Census Bureau. Delineation Files. Available from: https:\/\/www.census.gov\/programs-surveys\/metro-micro\/about\/delineation-files.html. [Cited 2022 Mar 3]."},{"issue":"12","key":"9909_CR25","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/cid\/ciz1215","volume":"71","author":"GP Wormser","year":"2020","unstructured":"Wormser GP, McKenna D, Karmen CL, Shaffer KD, Silverman JH, Nowakowski J, Wormser GP, McKenna D, Karmen CL, Shaffer KD, Silverman JH, Nowakowski J, Scavarda C, Shapiro ED, Visintainer P. Prospective evaluation of the frequency and severity of symptoms in Lyme disease patients with erythema migrans compared with matched controls at baseline, 6 months, and 12 months. Clin Infect Dis. 2020;71(12):3118\u201324. https:\/\/doi.org\/10.1093\/cid\/ciz1215.","journal-title":"Clin Infect Dis"},{"key":"9909_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijid.2022.01.033","volume":"116","author":"JN Aucott","year":"2022","unstructured":"Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. Int J Infect Dis. 2022;116:230\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2022.01.033.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"9909_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1086\/318082","volume":"183","author":"RA Kalish","year":"2001","unstructured":"Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis. 2001;183(3):453\u201360.","journal-title":"J Infect Dis"},{"issue":"2","key":"9909_CR28","first-page":"147","volume":"49","author":"K Bertakis","year":"2000","unstructured":"Bertakis K. Gender differences in the utilization of health care services. J Fam Pract. 2000;49(2):147\u201352.","journal-title":"J Fam Pract"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09909-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09909-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09909-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T09:24:10Z","timestamp":1700472250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09909-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9909"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09909-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Johns Hopkins Medicine Institutional Review Board and the Johns Hopkins HealthCare Data Sharing Committee. The need for informed consent was waived by the Johns Hopkins Medicine Institutional Review Board as a retrospective analysis of existing, de-identified data that does not involve direct interaction with human subjects. All research was performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JNA received consulting fees from the Pfizer North America Lyme Disease Vaccine Ad Board, has provided expert testimony in malpractice cases, and has been issued the following patent: Elevated CCL19 after completion of therapy for acute Lyme disease identifies patients at risk for development of post-treatment Lyme disease who will benefit from further antibiotic therapy. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"919"}}